BioSpace News Archive

Eli Lilly and Livongo Health, a leading consumer digital health company focused on empowering all people with chronic conditions to live better and healthier lives, today announced a strategic collaboration to study real-world evidence and develop new insights to reduce the burden on people living with diabetes.

Alder intends to use the cash to fund payments under Alder’s European patent settlement and global license agreement with Teva announced today.

The name change reflects the Company’s plan to exclusively focus on the late-stage clinical research and commercialization of gene-based biotherapeutics for niche markets in the oncology and cardiology spaces for patients with unmet medical needs.

The company plans to initiate a Phase 1 study designed to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary clinical activity of voruciclib in patients with B-cell malignancies.

Essential Medical today announced the completion of the 60-day follow up for the MANTA U.S. Pivotal Study.

In October, the company announced the initiation of this prospective, post-market lateral interbody fusion study designed to evaluate patient outcomes.

Acceleron today announced positive preliminary results for the first two cohorts in Part 1 of the Phase 2 clinical trial with ACE-083 in patients with facioscapulohumeral dystrophy (FSHD).

ARCA expects to report top-line Phase 2B data in March 2018.

Anthera expects to complete the second closing of the PIPE transaction on or about January 9, 2018.

A look at Xenon’s key goals for 2018.